Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$25.9MBeat by $1.4M
EPS$1.21Miss by $0.98
Revenue estimate$24.5M
EPS estimate$2.19

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$37.1M
EPS estimate$0.14

Financials

Q2 2025

Income statement

See full
Revenue$25.9M+482%
Gross profit$13.5M+1,441%
Operating income-$71.0M-199%
Net income$74.7M+475%
EPS (diluted)$1.21+352%

Balance sheet

See full
Cash & equivalents$47.7M+21.5%
Total debt$62.3M+4.7%
Total equity$117.2M+261%
Total assets$256.3M+77.5%

Cash flow

See full
Operating cash flow-$3.6M+81.2%
CapEx$213.0K—
Free cash flow-$3.8M+80.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$500.32M+144%
Enterprise value$514.88M+129%
P/E189.2×—
P/S8.1×-0.6×

Profitability

See full
Gross margin72%-3.2pp
Operating margin-192.1%-54.1pp
Net margin4.3%+2.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity3.5%+1.8pp
Debt / equity0.5×-1.3×
Current ratio7.9×+5.9×

Segments

By product

See full
MIPLYFFA$21.5M—
OLPRUVA$300.0K—

By segment

See full
Reportable Segment$25.9M+482%

FAQ

When did Zevra Therapeutics, Inc. report Q2 2025 earnings?
Zevra Therapeutics, Inc. (ZVRA) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Zevra Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Zevra Therapeutics, Inc. reported revenue of $25.9M and eps of $1.21 for Q2 2025.
Did Zevra Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $24.5M by $1.4M. EPS missed the consensus estimate of $2.19 by $0.98.
How did Zevra Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 481.7% from $4.4M a year earlier.
Where can I find Zevra Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-039883) and the 10-Q periodic report (0001628280-25-039967) directly on SEC EDGAR. The filing index links above go to sec.gov.